Michele Brannan, PA
Physician Assistant · Alton, ILNPI 1083621452
Payments from drug & device makers
Across 146 payments — averaging $19.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$475
- Novo Nordisk$404
- Amgen$264
- AstraZeneca$259
- AbbVie$217
- GSK$156
- plus $1K from 23 others
What the payments were for
- Food & beverage$2,72596%
- Education$1004%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 23 | $475 |
| Novo Nordisk | 22 | $404 |
| Amgen | 16 | $264 |
| AstraZeneca | 15 | $259 |
| AbbVie | 10 | $217 |
| GSK | 9 | $156 |
| Boehringer Ingelheim | 6 | $114 |
| Lundbeck LLC | 3 | $96 |
| Astellas Pharma US Inc | 4 | $94 |
| Novartis | 4 | $90 |
| Pfizer | 5 | $90 |
| Exact Sciences | 5 | $82 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 4 | $60 |
| Kowa Pharmaceuticals America, Inc. | 2 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $45 |
| Merck | 2 | $45 |
| Resmed Corp | 1 | $43 |
| Valinor Pharma, LLC | 2 | $30 |
| Verity Pharmaceuticals Inc. | 1 | $26 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $26 |
| Corcept Therapeutics | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Sanofi-aventis U.S. LLC | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $18 |
| Medtronic | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $16 |
| Abbott | 1 | $16 |
| Phadia US Inc. | 1 | $14 |
| Sumitomo Pharma America, Inc. | 1 | $6 |
How this compares
$2,825 in reported general payments places this provider in the 85th percentile of 3,912 physician assistant providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 238 | $214,387 |
| OzempicSemaglutide | 142 | $146,333 |
| JardianceEmpagliflozin | 142 | $142,899 |
| MounjaroTirzepatide | 54 | $67,227 |
| TrulicityDulaglutide | 43 | $51,330 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 68 | $46,492 |
| FarxigaDapagliflozin Propanediol | 39 | $30,045 |
| RybelsusSemaglutide | 17 | $24,210 |
| MyrbetriqMirabegron | 34 | $16,740 |
| Atorvastatin Calcium | 1,493 | $16,000 |
| VraylarCariprazine Hcl | 11 | $13,790 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $13,038 |
| XareltoRivaroxaban | 11 | $11,582 |
| Bydureon BciseExenatide Microspheres | 11 | $11,421 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 360 | $9,052 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $90 | $214,387238 claims |
| Novo NordiskOzempic, Rybelsus | $404 | $170,544159 claims |
| Boehringer IngelheimJardiance | $114 | $142,899142 claims |
| Lilly USA, LLCMounjaro, Trulicity | $475 | $118,55797 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $156 | $59,53092 claims |
| AstraZenecaFarxiga, Symbicort | $259 | $37,02955 claims |
| Astellas Pharma US IncMyrbetriq | $94 | $16,74034 claims |
| AbbVieVraylar | $217 | $13,79011 claims |
| MerckDulera | $45 | $6,52316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,912 physician assistant providers in Illinois.
Other physician assistant in Alton
- Andrew MastroChicago$419K
- Christopher AricoSkokie$407K
- Karlijn BurridgeWestmont$144K
- Ian MackeySkokie$135K
- Stephanie TraceyItasca$122K
- Olabimpe PhilipsAddison$103K
- Renata BlockChicago$103K
- Margaret RomanoChicago$82K
- Christina StarksChicago$77K
- Darrel CutlerHerrin$74K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.